Anti-PD1 and anti-PDL1 are now approved to treat lung cancer when targeted therapy is not available, such as in patients with KRAS mutations [60] that are not KRAS-G12C mutations, for which sotorasib is now approved. The gene discussed is CD274; the disease is lung carcinoma.